Home LiteratureArticle Details
PMID: 11466698 Published · ppublish English Clinical Trial Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.

A phase III study of radiation therapy plus carmustine with or without recombinant interferon-alpha in the treatment of patients with newly diagnosed high-grade glioma.

Cancer ·Vol. 92 ·No. 2 ·2001-07-15 ·Pages 420-33

Buckner JC, Schomberg PJ, McGinnis WL, Cascino TL, Scheithauer BW, O'Fallon JR, Morton RF, Kuross SA, Mailliard JA, Hatfield AK, Cole JT, Steen PD, Bernath AM

Abstract

The current study was conducted to determine whether the addition of interferon-alpha (IFN-alpha) to treatment with radiation therapy and carmustine (BCNU) improves time to disease progression or overall survival in patients with high-grade glioma. Patients with anaplastic astrocytoma, anaplastic oligoastrocytoma, glioblastoma multiforme, or gliosarcoma received radiation therapy plus BCNU as initial therapy. Subsequently, patients without tumor progression at the completion of radiation therapy were stratified by age, extent of surgery, tumor grade and histology, Eastern Cooperative Oncology Group performance status, and treating institution, and then were randomly assigned to receive either BCNU alone (200 mg/m(2) on Day 1) or BCNU (150 mg/m(2) on Day 3) plus IFN--alpha (12 million U/m(2) on Days 1-3, Weeks 1, 3, and 5) every 7 weeks for a maximum of 6 cycles. Of the 383 patients enrolled in the study, 275 eligible patients were randomized. There was no significant difference with regard to time to disease progression or overall survival between the two groups. Patients receiving IFN-alpha experienced more fever, chills, myalgias, and neurocortical symptoms including somnolence, confusion, and exacerbation of neurologic deficits. Cox multivariate regression models confirmed known favorable prognostic variables including younger age, Grade 3 tumor (according to World Health Organization criteria), and greater extent of surgery. Cox and classification and regression tree analysis models also demonstrated that a normal baseline Folstein mini-mental status examination (MMSE) score was associated with better prognosis. IFN-alpha does not appear to improve time to disease progression or overall survival in patients with high-grade glioma and appears to add significantly to toxicity. The baseline MMSE score may serve as an independent prognostic factor and warrants further investigation.

MeSH Terms
Adult Aged Antineoplastic Agents/administration & dosage,pharmacology Antineoplastic Agents, Alkylating/administration & dosage,pharmacology Antineoplastic Combined Chemotherapy Protocols/therapeutic use Brain Neoplasms/drug therapy,pathology,radiotherapy Carmustine/administration & dosage,pharmacology Combined Modality Therapy Disease Progression Female Glioma/drug therapy,pathology,radiotherapy Humans Interferon-alpha/administration & dosage,pharmacology Male Middle Aged Neoplasm Staging Survival Analysis Treatment Outcome
Chemicals
Antineoplastic Agents Antineoplastic Agents, Alkylating Interferon-alpha Carmustine
Authors & Affiliations
13 authors, click to expand affiliations / ORCID
Buckner J C
Mayo Clinic and Mayo Foundation, Rochester, Minnesota 55905, USA. buckner.jan@mayo.edu
Schomberg P J
McGinnis W L
Cascino T L
Scheithauer B W
O'Fallon J R
Morton R F
Kuross S A
Mailliard J A
Hatfield A K
Cole J T
Steen P D
Bernath A M
Article Info
Journal
Cancer
Abbr.
Cancer
ISSN
0008-543X
Published
2001-07-15
Pages
420-33
Language
English
Region
United States
NLM ID
0374236
Subset
IM
Grants
NCI NIH HHS · CA-15083 · United States
NCI NIH HHS · CA-25224 · United States
NCI NIH HHS · CA-35101 · United States
NCI NIH HHS · CA-35103 · United States
NCI NIH HHS · CA-35113 · United States
NCI NIH HHS · CA-35195 · United States
NCI NIH HHS · CA-35269 · United States
NCI NIH HHS · CA-35272 · United States
NCI NIH HHS · CA-35415 · United States
NCI NIH HHS · CA-35448 · United States
NCI NIH HHS · CA-37404 · United States
NCI NIH HHS · CA-37417 · United States
NCI NIH HHS · CA-52352 · United States
NCI NIH HHS · CA-60276 · United States
NCI NIH HHS · CA-63849 · United States
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com